Drug Profile
Research programme: biodefence antibodies - National Resilience
Alternative Names: Anti-H1N1 (swine flu) antibodies - XOMA; Anti-H5N1 (bird flu) antibodies - XOMA; Anti-influenza A antibodies - XOMA; Anti-severe acute respiratory syndrome (SARS) antibodies - XOMA; Antibotulinum toxin antibodies - XOMA; Antibotulism antibodies - XOMA; Biodefense antibodies - XOMA; F10 antibody - XOMA; XOMA 3EBLatest Information Update: 18 Jun 2021
Price :
$50
*
At a glance
- Originator Dana-Farber Cancer Institute; Harvard Medical School; University of California at San Francisco
- Developer XOMA
- Class Antibodies; Monoclonal antibodies
- Mechanism of Action Botulinum toxin inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Botulism; Influenza A virus H1N1 subtype; Influenza A virus H5N1 subtype; Severe acute respiratory syndrome
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Botulism in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-H1N1-subtype in USA (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Influenza-A-virus-H5N1-subtype in USA (Parenteral)